title: Interleukin-11-induced capillary leak syndrome in primary hepatic carcinoma patients with thrombocytopenia.
abstract: BACKGROUND
  Capillary leak syndrome (CLS) is a rare condition characterized by recurrent episodes of generalized edema and severe hypotension associated with hypoproteinemia. Interleukin-11 (IL-11) is a promising therapeutic agent for thrombocytopenia. A direct correlation between IL-11 and CLS has never been reported previously, particularly in patients with hepatic carcinoma.
  
  
  METHODS
  We describe two cases of CLS after IL-11 administration in two males with thrombocytopenia. Case 1 was a 46-year-old man with recurrence of hepatic carcinoma who was treated with IL-11 (3 mg per day). After four days of therapy, hypotension and hypoproteinemia were detected. The chest X-ray and B ultrasound of the abdomen showed pleural effusion and ascites. IL-11 was then discontinued, fluid resuscitation was performed, and fresh frozen plasma and packed red blood cells were transfused into this patient. The patient had recovered after 19 days of treatment. Case 2 was a 66-year-old man who had undergone radiofrequency ablation (RFA) for hepatic carcinoma. He was treated with IL-11 (3 mg per day) for thrombocytopenia. After two days of therapy, this patient complained of dyspnea with bilateral edema of the hands. Laboratory values showed hypoproteinemia. IL-11 was stopped and human albumin was transfused at a rate of 10 g per day. On the 4th day, fluid resuscitation was performed. The patient had recovered after treatment for two weeks.
  
  
  CONCLUSIONS
  The detection of IL-11-induced CLS supports the hypothesis that CLS could be a severe side effect of IL-11 treatment in some patients. These two case reports also demonstrate that patients with hepatic carcinoma who experience this rare form of CLS after treatment with IL-11 seem to respond to a therapeutic regimen that involves hydroxyethyl starch, albumin, and diuretic therapy. Liver cancer patients might be more susceptible to CLS because of poor liver function and hypersplenia. In addition, bleeding after RFA might be a further inducer of CLS.
authors: Department of Oncology, Sir Run Run Shaw Hospital, Medical School, Zhejiang University, Hangzhou, China.
authors: Wang
authors: W
authors: Kai-Feng
authors: Pan
authors: P
authors: Hong-Ming
authors: Lou
authors: L
authors: Hai-Zhou
authors: Shen
authors: S
authors: Li-Rong
authors: Zhu
authors: Z
authors: Xi-Yan
references: Am J Med. 2009 Jun;122(6):e5-7
references: 19486705
references: Biol Blood Marrow Transplant. 1998;4(3):134-41
references: 9923411
references: Cancer Chemother Pharmacol. 1996;38 Suppl:S99-102
references: 8765427
references: Br J Dermatol. 1992 Jul;127(1):64
references: 1637700
references: Intern Med. 2010;49(8):791-4
references: 20424373
references: Blood. 1996 May 1;87(9):3615-24
references: 8611685
references: Crit Care Med. 1980 Nov;8(11):661-2
references: 7428393
references: Arch Intern Med. 2002 Feb 25;162(4):481-2
references: 11863486
references: J Toxicol Clin Toxicol. 1996;34(6):713-9
references: 8941202
references: Ann Hematol. 2002 Oct;81(10):609-10
references: 12424546
references: Hematol J. 2003;4(1):54-6
references: 12692521
references: J Immunother. 2008 May;31(4):325-33
references: 18391763
references: Cardiol J. 2010;17(1):88-91
references: 20104463
references: Intern Med. 2007;46(12):899-904
references: 17575386
references: Clin Oncol (R Coll Radiol). 2006 Feb;18(1):90-1
references: 16477934
references: Eur J Cancer. 2001 Oct;37(15):1910-20
references: 11576848
references: Intern Med. 2007;46(18):1585-7
references: 17878647
references: J Clin Gastroenterol. 2010 May-Jun;44(5):374-80
references: 19809357
references: J Immunol. 2007 Sep 15;179(6):3715-23
references: 17785808
references: Q J Med. 1990 May;75(277):515-24
references: 2201996
references: Leuk Res. 2005 Jun;29(6):649-52
references: 15863204
references: Ann Intern Med. 2010 Jul 20;153(2):90-8
references: 20643990
references: Ann Pharmacother. 2010 Mar;44(3):587-9
references: 20150504